Why Is Adicet Bio (ACET) Stock Down -22.84% Today?
Key Takeaways
- Shares of ACET fell 22.84% to $6.96, down $2.06 from the prior session's close of $9.02.
- The decline followed the company's Phase 1 prula-cel data in lupus patients, which the company framed as positive but which underwhelmed elevated investor expectations.
- Reported efficacy — a 54% DORIS remission rate and 50% complete renal response at 12 months — was met with a "sell the news" reaction after a recent analyst price-target surge.
- The safety profile showed no CRS above Grade 2 but disclosed infections in 54% of patients, drawing scrutiny.
- Trading was briefly paused on a volatility halt before resuming, underscoring the day's outsized move.
- Investors now watch the planned pivotal lupus nephritis trial start-up in Q4 2026 and the next earnings report.
Opening Summary
ACET, or Adicet Bio, Inc., is a clinical-stage biotechnology company developing "off-the-shelf" allogeneic gamma delta CAR-T cell therapies for autoimmune diseases, hematologic malignancies, and solid tumors. Its lead candidate, prula-cel (formerly ADI-001), targets CD20 for the potential treatment of systemic lupus erythematosus (SLE). On Monday, the stock plunged 22.84% to $6.96, versus a prior close of $9.02, as the market reacted to the company's much-anticipated Phase 1 data release despite its "positive" framing.
Phase 1 Prula-cel Data Lands Below Elevated Expectations
The primary catalyst behind today's move was the company's announcement of safety and efficacy data from its Phase 1 study of prula-cel in patients with systemic lupus erythematosus with or without lupus nephritis. The readout covered 22 efficacy-evaluable patients (16 with lupus nephritis and six with extra-renal SLE) with follow-up ranging from six to 21 months.
At the 12-month mark, 54% of evaluable patients achieved DORIS remission and 50% of lupus nephritis patients achieved a complete renal response. While the company highlighted that all patients discontinued immunosuppressants and that nearly all tapered background steroids to 5 mg or less of prednisone equivalent, the headline efficacy figures fell short of the heightened bar set in recent sessions.
The stock had rallied roughly 9% in its prior session after H.C. Wainwright raised its price target to $34 from $27, calling prula-cel's profile "extremely attractive." That bullish revision elevated expectations into the data release, leaving the actual remission rates vulnerable to a classic "sell the news" reversal among a small, heavily-traded float.
Safety Profile and Market Reaction
Investors also weighed the safety data. The company reported no cytokine release syndrome (CRS) above Grade 2 and no cases of immune effector cell-associated neurotoxicity syndrome or hemophagocytic lymphohistiocytosis-like syndrome, which it cited as supportive of outpatient administration. However, infections were reported in 54% of safety-evaluable patients, with Grade 3 or higher infections in 8.3% — a detail that tempered enthusiasm alongside the modest sample size.
The magnitude of the move triggered a volatility trading pause shortly after the open, with trading later resuming. Such halts are common in small-cap biotech names with high beta and thin liquidity, and they can amplify a directional move once order flow returns.
Market Context and Trading Activity
The sell-off was accompanied by heavy trading activity, with volume running well above the stock's recent daily averages as investors repositioned around the binary data event. The move reflects company-specific, data-driven dynamics rather than broad-market weakness, given the idiosyncratic nature of a clinical readout for a micro-cap developer.
Technically, the decline pushed shares back below their 50-day moving average and toward levels last seen earlier in the quarter, erasing the prior session's advance and testing the lower end of the stock's recent trading range. The move underscores the volatility typical of pre-revenue biotechs, where a single clinical data point can dominate price discovery.
What Comes Next for ACET
Looking ahead, ACET plans to initiate start-up activities for a pivotal single-arm study in lupus nephritis during the fourth quarter of 2026, with a complete renal response at 12 months as the primary endpoint. The company also intends to discuss with the FDA the potential expansion of that pivotal study to include lupus patients without nephritis, citing the observed DORIS remission rate.
Additional milestones include a systemic sclerosis data update expected in the first half of 2027 and further lupus nephritis and SLE data by mid-2027. The company is scheduled to report quarterly results in early November. Risks remain substantial: prula-cel is still in early-stage development, the pivotal study has not begun enrollment, and Adicet will likely require additional financing to advance its pipeline, all of which could keep the shares volatile in the quarters ahead.
Trending AI Robots
For traders seeking a more systematic approach to navigating volatile names like ACET, Tickeron's Trending AI Robots page curates a selection of AI-driven trading bots. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this curated section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to match tools to their own objectives. Explore the page to see which automated strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ACET's Stochastic Oscillator sits in oversold zone for 5 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ACET's RSI Indicator exited the oversold zone, 25 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
Following a +12.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACET advanced for three days, in 239 of 284 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
ACET may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 144 of 171 cases where ACET Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACET as a result. In 76 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for ACET turned negative on September 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 39 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
ACET moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ACET crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACET declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.495) is normal, around the industry mean (26.780). P/E Ratio (6.061) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. ACET’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACET’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a distributor of pharmaceutical intermediate ingrediants and other industrial chemicals
Industry Biotechnology
Advertisement